Last reviewed · How we verify
N17350
At a glance
| Generic name | N17350 |
|---|---|
| Sponsor | Onchilles Pharma Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intratumoral N17350 in Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- N17350 CI brief — competitive landscape report
- N17350 updates RSS · CI watch RSS
- Onchilles Pharma Inc portfolio CI